At the start of 2021, 70 companies raised the price of hundreds of prescription drugs by an average of 3.3%.
The Federal Trade Commission filed a complaint in federal court against Vyera Pharmaceuticals, the company formerly known as Turing Pharmaceuticals that Martin Shkreli founded, alleging an “elaborate anticompetitive scheme to preserve a monopoly” on Daraprim.
Drugmakers including Bristol-Myers Squibb Co., Gilead Sciences Inc. and Biogen Inc. hiked U.S. list prices on more than 50 drugs to begin 2020, bringing total New Year’s Day drug price increases to more than 250, according to data analyzed by 3 Axis Advisors.
The United States pays more per capita for prescription drugs than any other country in the world, which is a huge concern for patients and insurance providers.
Johnson & Johnson raised U.S. prices on around two dozen prescription drugs, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto, all among the company’s top-selling products.
Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs, including the world’s top-selling medicine Humira, although the pace of price hikes was slower than during 2018.
The Centers for Medicare & Medicaid Services proposed a change in the payment amount for new drugs under its Part B program, amid the Trump administration’s attempts to tackle escalating prices of drugs.
As U.S. consumer outrage grows over prescription drug prices, state authorities and patient advocates in Maryland are preparing to enforce the nation’s first law designed to punish drugmaker price-gouging.
Hikma Pharmaceuticals Plc’s U.S. subsidiary raised the price of a common diarrhea drug by more than 400 percent and is charging more for five other medicines.
FDA plans to reorganize its drug review staff and create a SWAT team to eliminate a backlog of drugs for rare diseases and speed reviews of future applications.